The Roadmap identifies priorities for the development and implementation of new TB vaccines with the aim to coordinate and accelerate global action.
On 20 April 2021, the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Amsterdam Institute for Global Health and Development (AIGHD) have launched a global TB vaccine research and development roadmap at the Virtual Global Forum on TB Vaccines. It identifies priorities for the development and implementation of new TB vaccines with the aim to coordinate and accelerate global action. The project was carried out in close collaboration with the World Health Organization.
With more than 1.4 million deaths a year, TB is a major global public health challenge, especially in low- and middle-income countries. Ambitious global TB control goals have been established, but it is widely recognised that these will not be achieved without safe and effective vaccines. Despite the huge global burden of disease, there is little commercial incentive to develop new TB vaccines – no new vaccine has been introduced since bacillus Calmette-Guérin (BCG) in the 1920s. Addressing the need for new vaccines will require coordinated cross-sectoral partnerships and a focus on “end-to-end” development, from early-stage discovery research through to programmatic implementation.
For more information and to access the Roadmap, click here.